(TMO) Thermo Fisher Scientific - Overview
Sector: Healthcare | Industry: Diagnostics & Research | Exchange: NYSE (USA) | Market Cap: 166.590m USD | Total Return: 11.5% in 12m
Avg Turnover: 948M
EPS Trend: 92.1%
Qual. Beats: 3
Rev. Trend: 58.2%
Qual. Beats: 5
Warnings
Below Avwap Earnings
Tailwinds
Garp
Thermo Fisher Scientific Inc. (TMO) operates as a global leader in the life sciences tools and services sector, providing analytical instruments, reagents, consumables, and software. The company serves a diverse client base across pharmaceutical, biotechnology, academic, and government markets through four primary business segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services.
The company utilizes a diversified business model that integrates high-margin recurring revenue from consumables with large-scale clinical research services. In the life sciences industry, this razor-and-blade strategy is common, where the initial placement of diagnostic hardware drives long-term demand for proprietary testing kits and reagents. Additionally, the company acts as a Contract Development and Manufacturing Organization (CDMO), supporting the end-to-end production of vaccines and specialized drug therapies.
Reviewing the historical valuation metrics on ValueRay can provide further context on the companys long-term growth trends.
Headquartered in Waltham, Massachusetts, Thermo Fisher has expanded its global footprint since its founding in 1956. Its Specialty Diagnostics segment focuses on niche clinical areas, including allergy testing, autoimmune disease monitoring, and transplant diagnostics, ensuring a presence in critical healthcare infrastructure worldwide.
- Bioprocessing demand recovery accelerates revenue growth in Life Sciences Solutions segment
- Biopharma R&D spending levels dictate long-term contract research services margins
- Geopolitical tensions in China impact analytical instrument sales and supply chains
- High interest rates constrain capital equipment budgets for academic and government customers
- Strategic acquisitions and integration efficiency drive inorganic earnings per share expansion
| Net Income: 6.86b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -0.83 > 1.0 |
| NWC/Revenue: 17.03% < 20% (prev 23.79%; Δ -6.76% < -1%) |
| CFO/TA 0.07 > 3% & CFO 8.29b > Net Income 6.86b |
| Net Debt (39.9b) to EBITDA (11.2b): 3.58 < 3 |
| Current Ratio: 1.53 > 1.5 & < 3 |
| Outstanding Shares: last quarter (373.0m) vs 12m ago -1.58% < -2% |
| Gross Margin: 39.41% > 18% (prev 0.41%; Δ 3.90k% > 0.5%) |
| Asset Turnover: 42.57% > 50% (prev 43.31%; Δ -0.74% > 0%) |
| Interest Coverage Ratio: 5.89 > 6 (EBITDA TTM 11.2b / Interest Expense TTM 1.47b) |
| A: 0.07 (Total Current Assets 22.3b - Total Current Liabilities 14.6b) / Total Assets 113b |
| B: 0.54 (Retained Earnings 60.6b / Total Assets 113b) |
| C: 0.08 (EBIT TTM 8.66b / Avg Total Assets 106b) |
| D: 0.95 (Book Value of Equity 58.6b / Total Liabilities 61.3b) |
| Altman-Z'' = 3.74 = AA |
| DSRI: 0.89 (Receivables 9.20b/9.82b, Revenue 45.2b/42.9b) |
| GMI: 1.03 (GM 39.41% / 40.56%) |
| AQI: 1.06 (AQ_t 0.71 / AQ_t-1 0.67) |
| SGI: 1.05 (Revenue 45.2b / 42.9b) |
| TATA: -0.01 (NI 6.86b - CFO 8.29b) / TA 113b) |
| Beneish M = -3.03 (Cap -4..+1) = AA |
As of May 27, 2026, the stock is trading at USD 448.18 with a total of 1,936,754 shares traded.
Over the past week, the price has changed by +1.40%,
over one month by -4.24%,
over three months by -13.75% and
over the past year by +11.47%.
Thermo Fisher Scientific has received a consensus analysts rating of 4.39. Therefore, it is recommended to buy TMO.
- StrongBuy: 18
- Buy: 7
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 611.6 | 36.5% |
P/E Trailing = 24.6308
P/E Forward = 17.9856
P/S = 3.6859
P/B = 3.2078
P/EG = 1.4739
Revenue TTM = 45.2b USD
EBIT TTM = 8.66b USD
EBITDA TTM = 11.2b USD
Long Term Debt = 40.1b USD (from longTermDebt, last quarter)
Short Term Debt = 3.09b USD (from shortTermDebt, last quarter)
Debt = 43.2b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 39.9b USD (calculated: Debt 43.2b - CCE 3.26b)
Enterprise Value = 206b USD (167b + Debt 43.2b - CCE 3.26b)
Interest Coverage Ratio = 5.89 (Ebit TTM 8.66b / Interest Expense TTM 1.47b)
EV/FCF = 30.60x (Enterprise Value 206b / FCF TTM 6.75b)
FCF Yield = 3.27% (FCF TTM 6.75b / Enterprise Value 206b)
FCF Margin = 14.93% (FCF TTM 6.75b / Revenue TTM 45.2b)
Net Margin = 15.18% (Net Income TTM 6.86b / Revenue TTM 45.2b)
Gross Margin = 39.41% ((Revenue TTM 45.2b - Cost of Revenue TTM 27.4b) / Revenue TTM)
Gross Margin QoQ = 40.67% (prev 37.95%)
Tobins Q-Ratio = 1.82 (Enterprise Value 206b / Total Assets 113b)
Interest Expense / Debt = 3.41% (Interest Expense 1.47b / Debt 43.2b)
Taxrate = 4.04% (70.0m / 1.73b)
NOPAT = 8.31b (EBIT 8.66b * (1 - 4.04%))
Current Ratio = 1.53 (Total Current Assets 22.3b / Total Current Liabilities 14.6b)
Debt / Equity = 0.83 (Debt 43.2b / totalStockholderEquity, last quarter 51.9b)
Debt / EBITDA = 3.58 (Net Debt 39.9b / EBITDA 11.2b)
Debt / FCF = 5.91 (Net Debt 39.9b / FCF TTM 6.75b)
Total Stockholder Equity = 51.7b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.46% (Net Income 6.86b / Total Assets 113b)
RoE = 13.26% (Net Income TTM 6.86b / Total Stockholder Equity 51.7b)
RoCE = 9.43% (EBIT 8.66b / Capital Employed (Equity 51.7b + L.T.Debt 40.1b))
RoIC = 8.19% (NOPAT 8.31b / Invested Capital 101b)
WACC = 7.44% (E(167b)/V(210b) * Re(8.52%) + D(43.2b)/V(210b) * Rd(3.41%) * (1-Tc(0.04)))
Discount Rate = 8.52% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -92.01 | Cagr: -1.74%
[DCF] Terminal Value 75.49% ; FCFF base≈6.74b ; Y1≈6.79b ; Y5≈7.23b
[DCF] Fair Price = 195.1 (EV 112b - Net Debt 39.9b = Equity 72.5b / Shares 371.6m; r=8.35% [WACC [floored]]; 5y FCF grow 0.36% → 2.50% )
EPS Correlation: 92.12 | EPS CAGR: 3.23% | SUE: 1.35 | # QB: 3
Revenue Correlation: 58.22 | Revenue CAGR: 1.30% | SUE: 1.40 | # QB: 5
EPS current Quarter (2026-06-30): EPS=5.72 | Chg30d=-1.58% | Revisions=-56% | Analysts=17
EPS next Quarter (2026-09-30): EPS=6.35 | Chg30d=-1.09% | Revisions=+52% | Analysts=20
EPS current Year (2026-12-31): EPS=24.86 | Chg30d=+0.27% | Revisions=+33% | GrowthEPS=+8.7% | GrowthRev=+7.2%
EPS next Year (2027-12-31): EPS=27.30 | Chg30d=+0.57% | Revisions=-20% | GrowthEPS=+9.8% | GrowthRev=+5.4%
[Analyst] Revisions Ratio: -56%